MAPS, Eight Capital And Integrated V.C. Backs Numinus $6M Offering
The TDR Three Takeaways:
COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady Quarter And ‘Strong Progress Across The Business’
Psychedelics biotech COMPASS Pathways’ (NASDAQ: CMPS) consolidated unaudited financial results for the second quarter 2023, ended June 30 are as follows:
Psychedelics And Treatment-Resistant Depression: Reactions To COMPASS’ Published Results
(Part two of a four-part series)
See previous story in this series: Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS’ Latest Trial Outcomes